WEST PACES ADVISORS INC. reported CASI PHARMACEUTICALS INC COM NEW (CASI) in 7 quarterly 13F filings from 2024 Q1 through 2026 Q2. The latest visible filing shows CASI at 0.00% of the fund.
This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.
This page is designed to answer the real investor question behind a 13F filing: how meaningful was WEST PACES ADVISORS INC.'s position in CASI PHARMACEUTICALS INC COM NEW, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.
CASI was reported at 0.00% of portfolio in the most recent visible filing.
Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.
Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.
Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.
These are the practical questions this page is built to answer before you even open the full history table.
WEST PACES ADVISORS INC. reported CASI across 6 quarterly 13F filings, from 2024 Q1 through 2026 Q2.
The largest reported portfolio weight for CASI was 0.00% in 2024 Q3.
The most recent filing on this page is 2026 Q2, when WEST PACES ADVISORS INC. reported 100 shares, equal to 0.00% of portfolio, with an estimated market value of $17.
The chart compares WEST PACES ADVISORS INC.'s quarterly CASI portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.